Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing Spondylitis

Next Previous
X
Search
Trial Profile

A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing Spondylitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Adverse reactions
  • Acronyms BE AGILE 2
  • Sponsors UCB; UCB Biopharma

    • Most Recent Events

    • 15 Jun 2024 Results reporting 5-year long-term safety and efficacy data from this trial and its OLE presented at the 25th Annual Congress of the European League Against Rheumatism
    • 15 Nov 2023 5-yr results of Bimekizumab in BE AGILE and its OLE, presented at the ACR Convergence 2023
    • 15 Nov 2023 Results of pooled analysis of studies (BE MOBILE 1, BE MOBILE 2, BE MOVING,BE MOBILE 1,BE MOBILE 2,BE AGILE, BE AGILE 2, assessing incidence of uveitis following inhibition of IL-7A in addition to IL-7F with bimekizumab in patients with Axial Spondyloarthritis were presented at the ACR Convergence 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top